Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes.

ABSTRACT:

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of lymphoma, yet many patients relapse. Several prognostic markers have been associated with CAR T-cell outcomes, such as tumor burden, response to bridging chemotherapy, and laboratory parameters at the time of lymphodepletion or infusion. The effect of cancer cachexia and weight loss before CAR T cells on toxicity and outcomes is not well understood. Here, we present a retrospective single-institution cohort study of 259 patients with lymphoma treated with CAR T cells between 2017 and 2023. We observed that patients with >5% decrease in their body mass index in the 3 months preceding CAR T-cell treatment (weight loss group; all meeting one of the commonly accepted definitions of cancer cachexia) had

SUBMITTER: Valtis YK 

PROVIDER: S-EPMC11750447 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature